Advertisements


We are Sorry, This Page doesn't Exist


Flex Pharma Down on Workforce Reduction, Ends Phase II Study

Flex Pharma (FLKS) announced that the company is ending the phase II studies for its pipeline candidate FLX-787 in two indications. The company also plans to lower its workforce by about 60%. F.....»»

Category: smallbizSource: nytJun 14th, 2018

Technical Take: Spectrum rallies on Anerson"s Phase 2 data of poziotinib

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallApr 10th, 2018

Agenus Receives Milestone Payment of $5 Million from Incyte

Agenus (AGEN) receives a milestone payment of $5 million from Incyte on the initiation of a phase I study of INCAGN2385. Agenus Inc. .....»»

Category: dealsSource: nyt8 hr. 19 min. ago

Hawaiian, Japan Airlines expand frequent flyer program

As the second phase of their comprehensive partnership launched in March, Hawaiian Airlines and Japan Airlines will offer reciprocal frequent flyer benefits starting Oct. 1. HawaiianMiles members will be able to collect and redeem miles on all inte.....»»

Category: topSource: bizjournals8 hr. 49 min. ago

First phase of Norterra office sells, second planned for construction

JDM III Norterra, an investment fund managed by JDM Partners, consisting of Jerry Colangelo, David Eaton and Mel Schultz, bought the first phase of the development......»»

Category: topSource: bizjournals11 hr. 19 min. ago

Viking price target raised to $43 after Phase 2 data at Raymond James

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewall12 hr. 19 min. ago

44 Stocks Moving In Tuesday"s Mid-Day Session

Gainers Viking Therapeutics, Inc. (NASDAQ: VKTX) climbed 87.8 percent to $19.51 after announcing top-line results from Phase 2 study of VK2809. The study achieved primary endpoint. read more.....»»

Category: blogSource: benzinga13 hr. 4 min. ago

Relmada says top-line data from Phase 2 MDD study expected in first half of 2019

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewall16 hr. 19 min. ago

Zealand Pharma achieves endpoints in Phase 3 trial with dasiglucagon

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewall19 hr. 19 min. ago

Viking Therapeutics up 136% after Phase 2 study of VK2809 meets endpoint

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewall19 hr. 19 min. ago

Iterum Therapeutics initiates two Phase 3 clinical trials for sulopenem

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewall19 hr. 19 min. ago

Market evolving favorably for Ascendis into Phase III results, says JPMorgan

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewall19 hr. 19 min. ago

IMV Inc announces initial data from Phase 2 trial of DPX-Survivac with Keytruda

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewall19 hr. 19 min. ago

22 Stocks Moving In Tuesday"s Pre-Market Session

Gainers Viking Therapeutics, Inc. (NASDAQ: VKTX) rose 135.8 percent to $24.50 in pre-market trading after announcing top-line results from Phase 2 study of VK2809. The study achieved primary endpoint. read more.....»»

Category: blogSource: benzinga19 hr. 19 min. ago

Viking Therapeutics announces results from Phase 2 study of VK2809

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewall20 hr. 34 min. ago

Japanese Yen: USD/JPY (JPY=X) looks set for pullback

Japanese Yen: USD/JPY (JPY=X) looks set for pullback USD/JPY¬†is turning lower at the start of the week, with the pair hoping to move into a retracement phase fol.....»»

Category: topSource: livetradingnewsSep 17th, 2018

Pfizer"s Skin Disease Candidates Positive in Mid-Stage Study

Pfizer's (PFE) JAK inhibitor candidates -- PF-06651600 and PF-06700841 -- demonstrate improvements in moderate to severe alopecia areata patients in a phase II study. Pfizer Inc. PFE announced positive top-line data from a phase IIa.....»»

Category: personnelSource: nytSep 17th, 2018

Argenx reports Phase 2 proof-of-concept clinical trial of efgartigimod

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallSep 17th, 2018

Menlo Therapeutics initiates enrollment in second Phase 3 trial of serlopitant

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallSep 17th, 2018

Theravance Biopharma, Mylan report data from Phase 3 studies of YUPELRI

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallSep 17th, 2018